The major human urinary trypsin inhibitor is a proteoglycan

Area of Science:

• Biochemistry
• Glycobiology
• Proteomics

Background:

• Human urine contains a major urinary trypsin inhibitor.
• This inhibitor has a molecular mass of approximately 44,000 Da.
• The inhibitor's structure and composition are not fully characterized.

Purpose of the Study:

• To characterize the carbohydrate moiety of the major urinary trypsin inhibitor.
• To determine the nature and linkage of the glycosaminoglycan chain.
• To investigate the functional significance of the carbohydrate component on trypsin inhibition.

Main Methods:

• Isolation and purification of the major urinary trypsin inhibitor from human urine.
• Compositional analysis of the carbohydrate moiety, including sugar identification and quantification.
• Enzymatic digestion studies using chondroitinase ABC and testicular hyaluronidase.
• Analysis of molecular mass changes before and after enzymatic treatment using SDS-PAGE.

Main Results:

• The inhibitor comprises 35% carbohydrate, including N-acetylglucosamine, mannose, galactose, hexuronic acid, and N-acetylgalactosamine.
• The carbohydrate moiety is an integral glycosaminoglycan, resistant to dissociation under various denaturing conditions.
• The glycosaminoglycan chain is sensitive to chondroitinase ABC and testicular hyaluronidase, consistent with slightly sulfated chondroitin 4-sulfate or 6-sulfate.
• Enzymatic digestion reduced the inhibitor's molecular mass to 26,000 Da while preserving trypsin inhibitory activity.

Conclusions:

• The major urinary trypsin inhibitor contains an integral glycosaminoglycan chain, likely a slightly sulfated chondroitin sulfate.
• This glycosaminoglycan component is crucial for the inhibitor's structural integrity but not essential for its trypsin inhibitory function.
• Further studies are warranted to elucidate the precise role of the glycosaminoglycan in inhibitor function and physiological relevance.